Gruppo Italiano Malattie EMatologiche dell'Adulto
gimema.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
132
Active
35
Phase 3
9
Total enrollment
35,357
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ponatinib + Blinatumomab | — | — | — | — | — | 1 | |
| Chemotherapy + Imatinib | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Standard Chemotherapy | — | — | — | — | — | 1 | |
| Gemtuzumab Ozogamicin | — | — | — | — | — | 1 | |
| Ponatinib | — | — | — | — | 4 | ||
| Nilotinib | — | — | — | 6 | |||
| Ibrutinib 420 mg | — | — | — | — | — | 1 | |
| Teclistamab | — | — | — | — | — | 1 | |
| Daratumumab plus chemotherapy according to the national treatment program | — | — | — | — | — | 1 | |
| Venetoclax+Decitabine | — | — | — | — | — | 1 | |
| Inotuzumab Ozogamicin | — | — | — | — | — | 1 | |
| VenObi+Ven or VenObi+VenZan | — | — | — | — | — | 1 | |
| Gilteritinib | — | — | — | — | — | 1 | |
| Asciminib | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | 3 | ||
| serologic response evaluation | — | — | — | — | — | 1 | |
| Biological characterization of AML with MECOM or atypical 3q26 rearrangements | — | — | — | — | — | 1 |
Next readouts
- 2023-01-31
- 2024-10-25
- 2024-11
- 2025-04
- 2025-05
- 2025-11
- 2026-03-01
- 2026-03-01
- 2026-05
- 2026-07-15
Top conditions
- Chronic Lymphocytic Leukemia15
- Chronic Myeloid Leukemia15
- Acute Myeloid Leukemia14
- Leukemia9
- Acute Lymphoblastic Leukemia9
- Acute Promyelocytic Leukemia5
- Myelodysplastic Syndromes5
- Multiple Myeloma4
Frequently asked questions about Gruppo Italiano Malattie EMatologiche dell'Adulto
- How many clinical trials does Gruppo Italiano Malattie EMatologiche dell'Adulto have on ClinicalTrials.gov?
- Gruppo Italiano Malattie EMatologiche dell'Adulto is listed as the lead sponsor on 132 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gruppo Italiano Malattie EMatologiche dell'Adulto's trials are in Phase 3?
- 9 of Gruppo Italiano Malattie EMatologiche dell'Adulto's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Gruppo Italiano Malattie EMatologiche dell'Adulto focus on?
- Gruppo Italiano Malattie EMatologiche dell'Adulto's most-studied conditions on ClinicalTrials.gov are Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Leukemia, Acute Lymphoblastic Leukemia.
- When are Gruppo Italiano Malattie EMatologiche dell'Adulto's next clinical trial readouts?
- Gruppo Italiano Malattie EMatologiche dell'Adulto has 10 upcoming primary-completion readouts tracked here; the soonest is “Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy”, expected around 2023-01-31.